Document is current

Article History

Received: 22 October 2020

Accepted: 13 November 2020

First Online: 3 January 2021

Compliance with ethical standards

:

: Each of the 12 participating sites received approval from their respective, local institutional review boards. This study was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all individual participants included in the study.

: Dr. Wu has nothing to disclose. Dr. Liu reports serving on the Advisory board for Pfizer and Heron Therapeutics. Dr. Offin reports personal fees from PharmaMar, personal fees from Novartis, personal fees from Targeted Oncology, personal fees from Bristol-Myers Squibb, personal fees from Merck Sharp & Dohme, outside the submitted work. Drs. Lezcano, Torrisi, and Brownstein have nothing to disclose. Dr. Hyman owns stock in Fount Therapeutics, has served on advisory boards for ArQule, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, CytomX, Debiopharm, Fount Therapeutics, Genentech, Eli Lilly, Janssen, Jazz Pharma, Pfizer, and Puma Biotechnology, received research funding from AstraZeneca, Bayer, Loxo Oncology, and Puma Biotechnology, and received travel expenses from Chugai Pharma and Genentech; he is currently employed by and holds equity in Loxo Oncology, a subsidiary of Eli Lilly. Dr. Gounder has received honoraria from Bayer and Flatiron Health, served on advisory boards for Bayer, Boehringer Ingelheim, Epizyme, Daiichi Sankyo, Karyopharm, and Springworks Therapeutics, served on a speakers’ bureau for Amgen, and received travel expenses from Epizyme. Dr. Abida reports receiving honoraria from CARET, consulting for Clovis Oncology, Janssen, MORE Health, ORIC Pharmaceuticals, Daiichi Sankyo, research funding from AstraZeneca, Zenith Epigenetics, Clovis Oncology, GlaxoSmithKline, and travel expenses from GlaxoSmithKline, Clovis Oncology, ORIC Pharmaceuticals. Dr. Drilon reports honoraria/advisory board participation from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Roche, Novartis, EMD Serono, MJH, Faculty RTP, Medendi; associated research paid to the institution from Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, PharmaMar; research from Foundation Medicine; royalties from Wolters Kluwer; other support from Merck, Puma, Merus, Boehringer Ingelheim; and CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD. Dr. Harding reports consulting fees from Bristol Myers Squibb, CytomX, Eli Lilly, Eisai, Exelixis, Imvax, QED, and research funding from Bristol Myers Squibb. Dr. Sullivan reports research funding from Merck, Amgen; and Consulting/Advisory Board Membership with Asana Biosciences, Bristol Myers Squibb, Eisai, Iovance, Merck, Novartis, Pfizer. Dr. Janku has institutional research support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Synlogic, SpringBank Pharma, Agios, Plexxikon, Deciphera, Piqur, FujiFilm Pharma, Symphogen, Bristol-Myers Squibb, Asana, Astex, Sotio, SQZ, Bicara, JS Innopharm and Proximagen; is or has been on the Scientific Advisory Boards of Guardant Health, IFM Therapeutics, Synlogic, Bicara, Asana, PureTech Health, Synlogic and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. Dr. Welsch is an employee of ImmunoMet Therapeutics. Dr. Varterasian has nothing to disclose. Dr. Groover is an employee of Biomed Valley Discoveries. Dr. Li is a consultant/advisor at Roche/Genentech, Biosceptre International, Thermo Fisher Scientific, Mersana Therapeutics, Hengrui Therapeutics, and Guardant Health, reports receiving commercial research grants from Roche/Genentech, Daiichi Sankyo, Amgen, Lilly, Hengrui Therapeutics, Illumina, Guardant Health, BioMed Valley Discoveries, AstraZeneca, GRAIL, and MORE Health, and has ownership interest in two institutional patents at Memorial Sloan Kettering Cancer Center (US62/685,057, US62/514,661). Dr. Lacouture reports acting as consultant/advisory role for Legacy Healthcare Services, Apricity Health, LLC, Azitra, Inc., Deciphera, Galderma Research and Development, Johnson and Johnson, NCODA, Novocure Inc., Kyowa Kirin, Inc., Loxo, Merck Sharp and Dohme Corporation, Janssen Research & Development, LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, QED Therapeutics, F. Hoffmann-La Roche AG, Amgen Inc., Astrazeneca Pharmceuticals LP, Genentech, Inc., Seattle Genetics, Lutris, Paxman Coolers, OnQuality Pharmaceuticals Ltd., Takeda Millenium, and research funding from Veloce, US Biotest, Lutris, Paxman.

: Not applicable.